Spies, Marie
Klöbl, Manfred
Höflich, Anna
Hummer, Allan
Vanicek, Thomas
Michenthaler, Paul
Kranz, Georg S. http://orcid.org/0000-0002-3892-1804
Hahn, Andreas
Winkler, Dietmar http://orcid.org/0000-0001-8849-9907
Windischberger, Christian
Kasper, Siegfried
Lanzenberger, Rupert http://orcid.org/0000-0003-4641-9539
Funding for this research was provided by:
Oesterreichische Nationalbank (P14193, P14193, P14193, P14193, P14193, P14193, P14193, P14193, P14193, P14193)
National Alliance for Research on Schizophrenia and Depression (23741)
Article History
Received: 6 November 2018
Accepted: 26 June 2019
First Online: 7 August 2019
Competing Interests
: Marie Spies has received travel grants from Janssen-Cilag Pharma GmbH, Eli Lilly, AOP Orphan Pharamceuticals A.G., and Austroplant, speaker honoraria from Janssen-Cilag Pharma GmbH and Austroplant and workshop participation from Eli Lilly. Thomas Vanicek has received travel grants and compensation for workshop participation from Pfizer and Eli Lilly and speaker honoraria from Shire. Georg Kranz has received travel grants from Roche, AOP Orphan Pharmaceuticals A.G. and Pfizer. Dietmar Winkler received lecture fees from Angelini, Lundbeck and Pfizer. Siegfried Kasper received grants/research support, consulting fees and/or honoraria within the last three years from Angelini, AOP Orphan Pharmaceuticals A.G., Celegne GmbH, Eli Lilly, Janssen-Cilag Pharma GmbH, KRKA-Pharma, Lundbeck A/S, Mundipharma, Neuraxpharm, Pfizer, Sanofi, Schwabe, Servier, Shire, Sumitomo Dainippon Pharma Co. Ltd. and Takeda. Rupert Lanzenberger received travel grants and/or conference speaker honoraria from Shire, AstraZeneca, Lundbeck A/S, Dr. Willmar Schwabe GmbH, AOP Orphan Pharmaceuticals A.G., Janssen-Cilag Pharma GmbH, and Roche Austria GmbH. All other authors declare no conflict of interest.